IXI vs. SBTX, SAR, AREC, COS, C4XD, DDDD, OKYO, POLB, AOR, and APTA
Should you be buying IXICO stock or one of its competitors? The main competitors of IXICO include SkinBioTherapeutics (SBTX), Sareum (SAR), Arecor Therapeutics (AREC), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), OKYO Pharma (OKYO), Poolbeg Pharma (POLB), AorTech International (AOR), and Aptamer Group (APTA). These companies are all part of the "biotechnology" industry.
IXICO vs. Its Competitors
IXICO (LON:IXI) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.
12.8% of IXICO shares are owned by institutional investors. Comparatively, 3.4% of SkinBioTherapeutics shares are owned by institutional investors. 6.0% of IXICO shares are owned by insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, IXICO's average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.
IXICO has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, SkinBioTherapeutics has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.
IXICO has a net margin of -31.10% compared to SkinBioTherapeutics' net margin of -237.95%. IXICO's return on equity of -19.14% beat SkinBioTherapeutics' return on equity.
IXICO has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.
Summary
IXICO beats SkinBioTherapeutics on 8 of the 11 factors compared between the two stocks.
Get IXICO News Delivered to You Automatically
Sign up to receive the latest news and ratings for IXI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (LON:IXI) was last updated on 10/9/2025 by MarketBeat.com Staff
